How long do results last with PRP vs polynucleotides?
How long do results last with PRP vs polynucleotides? Early studies suggest comfort gains for some people with genitourinary syndrome of menopause (GSM) can build over weeks and may soften across months. Many plans review at 3–6 months and again around 6–12 months to decide on maintenance. Durability varies and depends on getting foundations right—regular moisturiser, a suitable lubricant, and, when needed, local vaginal oestrogen or DHEA. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
How long do results last with PRP vs polynucleotides? Both platelet-rich plasma (PRP) and polynucleotide injectables aim to condition superficial vulvo-vaginal tissues so movement and intimacy feel more comfortable in genitourinary syndrome of menopause (GSM). PRP concentrates your own platelets and growth factors to nudge a repair response; polynucleotides (highly purified DNA fragments) are biostimulatory and water-binding, used to support extracellular matrix quality and slip. Neither corrects the low-oestrogen biology that drives GSM; they are considered adjuncts after foundations. In practice, improvements—when they occur—tend to develop over several weeks and can soften again over months, which is why most plans schedule review points rather than promising lasting outcomes from a single visit.
Typical timeline people report. After an initial series (often 2–3 sessions 4–8 weeks apart), many describe calmer day-to-day movement, fewer “paper-cut” micro-tears at the vestibule/posterior fourchette, and easier initial penetration by 6–12 weeks. Some hold these gains for a few months with a scheduled moisturiser and generous, compatible lubricant; others notice a gradual fade by 6–12 months and decide whether a top-up is worthwhile. Because polynucleotides focus on superficial hydration and matrix quality, some find the “dewier” feel comes on a touch earlier; PRP responses can feel steadier once established—but individual variation is the rule.
What determines durability most. 1) Foundations: a regular vaginal moisturiser (many prefer hyaluronic-acid gels) and a suitable personal lubricant for higher-friction moments—water-based (versatile/condom-friendly), silicone-based (long glide for vestibular tenderness), or oil-based (rich feel but may degrade latex condoms/toys). 2) Targeting: if burning is entrance-focused, fingertip-apply any local therapy directly to the vestibule; internal-only use often misses the sore spot. 3) Biology support: when acceptable, local vaginal oestrogen (or vaginal DHEA) helps maintain epithelial maturity and a healthier pH, making any injectable gains last longer. 4) Co-drivers: contact irritants (perfumed washes/liners), tight sports kit, saddle pressure, recurrent BV/thrush/UTIs, or pelvic floor guarding can erode improvements unless addressed.
Planning reviews and maintenance. A sensible structure is: initial series → review at 3–6 months to judge real-world change (sting with urine contact, micro-tears, dyspareunia, speculum tolerance) → consider a single top-up or continue foundations alone → reassess around 6–12 months. If progress stalls after two sessions, pause and re-check the diagnosis (e.g., vestibulodynia, lichen sclerosus), ensure local products are reaching the vestibule, and add pelvic health physiotherapy if protective muscle over-activity is maintaining pain—injectables cannot relax muscles.
Where this sits in a UK pathway. First-line care emphasises non-hormonal basics (moisturisers and lubricants) and, when quality of life is affected, adding low-dose local vaginal oestrogen. Devices (laser/RF) and injectables are considered after guideline-led steps. For a practical view of how treatment steps are sequenced and to plan budgets/timelines via treatment prices, see our clinic pages.
Bottom line. Expect any PRP or polynucleotide benefit to be gradual and time-limited. Durability depends far more on steady foundations and accurate placement than on the product label. Review regularly and aim to maintain the lowest effective routine once comfortable.
Clinical Context
Who may notice longer-lasting gains? People who keep a structured moisturiser routine, choose a lubricant that truly suits their needs (silicone-based often gives longest glide for vestibular tenderness), and, when acceptable, add local oestrogen/DHEA to support epithelial maturity. Those who target the entrance precisely—whether with fingertip-applied cream or injection placement—generally fare better.
Who may see quicker fade? Anyone with ongoing irritants (fragranced washes, tight/synthetic kit, chlorine without rinsing), untreated infections, or mis-targeted care (internal-only when the vestibule is the hotspot). If deep pelvic pain dominates despite surface comfort, consider other drivers (e.g., endometriosis, adenomyosis, pelvic floor over-activity) rather than repeating injectables.
Next steps. Map symptoms; optimise moisturiser + lubricant; consider local oestrogen or DHEA if acceptable; and plan reviews at 3–6 and 6–12 months. Defer procedures if you have active BV/thrush/UTI, malodorous discharge, fever, unexplained bleeding, or recent pelvic/perineal surgery without clearance.
Evidence-Based Approaches
Guideline first lines (UK): Patient-facing NHS summaries outline symptoms and self-care for vaginal dryness. The NICE Menopause Guideline (NG23) recommends vaginal moisturisers and lubricants first and considering low-dose local vaginal oestrogen when GSM affects quality of life.
Product and prescribing detail: UK product information and cautions for local therapies (vaginal oestrogens, prasterone/DHEA) are in the British National Formulary (BNF).
Comparators with stronger evidence: Cochrane reviews report that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings—providing the benchmark for symptom relief and maintenance (Cochrane Library).
Emerging evidence for injectables: Peer-reviewed overviews and small trials/case series of PRP and polynucleotides in GSM and vestibular pain suggest potential benefit but highlight heterogeneity of preparation, dosing and follow-up; larger controlled studies are needed before routine use. See representative abstracts on PubMed.
Applying the evidence: Use a stepped plan—foundations → add local therapy if needed → consider injectables only as adjuncts in selected cases, with transparent discussion of likely timelines (weeks to build; months to fade) and the role of maintenance reviews. ® belongs to its owner.